CSTB Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P04080 |
---|---|
Clone Names | 100430277 |
Gene ID | 1476 |
---|---|
Other Names | Cystatin-B, CPI-B, Liver thiol proteinase inhibitor, Stefin-B, CSTB, CST6, STFB |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CSTB |
---|---|
Synonyms | CST6, STFB |
Function | This is an intracellular thiol proteinase inhibitor. Tightly binding reversible inhibitor of cathepsins L, H and B. |
Cellular Location | Cytoplasm. Nucleus |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The cystatin superfamily encompasses proteins that containmultiple cystatin-like sequences. Some of the members are activecysteine protease inhibitors, while others have lost or perhapsnever acquired this inhibitory activity. There are three inhibitoryfamilies in the superfamily, including the type 1 cystatins(stefins), type 2 cystatins and kininogens. This gene encodes astefin that functions as an intracellular thiol protease inhibitor.The protein is able to form a dimer stabilized by noncovalentforces, inhibiting papain and cathepsins l, h and b. The protein isthought to play a role in protecting against the proteases leakingfrom lysosomes. Evidence indicates that mutations in this gene areresponsible for the primary defects in patients with progressivemyoclonic epilepsy (EPM1).
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Ceru, S., et al. J. Biol. Chem. 285(13):10078-10086(2010)Skerget, K., et al. J. Biol. Chem. 285(5):3201-3210(2010)Ceru, S., et al. Biol. Cell 102(6):319-334(2010)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.